Valuation: Caplin Point Laboratories Limited

Market Cap 210B 2.19B 1.91B 1.8B 1.64B 3.07B 3.07B 21.51B 8.29B 107B 8.22B 8.03B 344B P/E 2027 *
28.8x
P/E 2028 * 24.9x
Enterprise Value 210B 2.19B 1.91B 1.8B 1.64B 3.07B 3.07B 21.51B 8.29B 107B 8.22B 8.03B 344B EV / Sales 2027 *
8.36x
EV / Sales 2028 * 7.39x
Free-Float
26.56%
Yield 2027 *
0.15%
Yield 2028 * 0.15%
1 day+0.33%
1 week+0.08%
Current month+9.52%
1 month+8.95%
3 months+10.01%
6 months+71.84%
Current year+49.73%
1 week 2,490.35
Extreme 2490.35
2,815.95
1 month 2,455
Extreme 2455
2,874
Current year 1,502.45
Extreme 1502.45
2,874
1 year 1,502.45
Extreme 1502.45
2,874
3 years 950
Extreme 950
2,874
5 years 575
Extreme 575
2,874
10 years 180
Extreme 180
2,874
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Director/Board Member 71 2015-03-27
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%+0.08%+17.59%+169.33% 2.18B
+1.72%+1.57%+12.86%+62.07% 45.94B
-1.02%-1.90%+36.59%+101.89% 37.22B
+0.09%+3.74%+11.93%+85.83% 12.06B
-0.60%+1.47%-12.04%+11.81% 11.74B
-0.38%-0.38%+18.81%+142.06% 9.03B
+0.55%+2.71%+28.61%+42.86% 7.36B
+0.11%+1.27%+17.49%+186.01% 7.2B
-0.06%+2.97%+39.67%-17.58% 7.15B
+3.26%+4.39%-40.07%+11.31% 5.03B
Average +0.35%+1.56%+13.14%+79.56% 14.49B
Weighted average by Cap. +0.34%+0.45%+17.82%+76.29%

Financials

2027 *2028 *
Net sales 25.07B 262M 228M 215M 196M 367M 367M 2.57B 992M 12.77B 983M 961M 41.21B 28.34B 296M 258M 243M 221M 415M 415M 2.91B 1.12B 14.44B 1.11B 1.09B 46.59B
Net income 7.26B 75.83M 66.11M 62.27M 56.71M 106M 106M 746M 287M 3.7B 285M 279M 11.94B 8.41B 87.8M 76.55M 72.1M 65.66M 123M 123M 863M 333M 4.28B 330M 322M 13.83B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
4,199
Date Price Change Volume
26-09-21 2,756.90 +0.33% 3,266
26-09-18 ₹2,747.85 +5.87% 13,055
26-09-17 ₹2,595.45 +0.45% 5,419
26-09-16 ₹2,583.70 +0.50% 26,442
26-09-15 ₹2,570.80 -6.68% 9,379
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,756.90INR
Average target price
2,765.00INR
Spread / Average Target
+0.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!